Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity

S. Zarnegar‐Lumley; C.A. Stone; C.M. Smith; L.L. Hall; K.E. Luck; G. Koo; J.H. Plager; E.J. Phillips; D.L. Friedman

doi:10.1002/pbc.29686

Back

Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity

Journal article

Peer reviewed

Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity

S. Zarnegar‐Lumley, C.A. Stone, C.M. Smith, L.L. Hall, K.E. Luck, G. Koo, J.H. Plager, E.J. Phillips and D.L. Friedman

Pediatric Blood & Cancer, Vol.69(7), Art. e29686

2022

DOI: https://doi.org/10.1002/pbc.29686

Files and links (1)

url

Free to Read *No subscription requiredView

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID-19) and is important for oncology patients. mRNA-based COVID-19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG-ASNase) and those with PEG-ASNase-associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID-19 vaccines. We, therefore, surveyed oncologists on COVID-19 vaccine counseling practice and vaccination outcomes in COVID-19 vaccination-eligible patients and show safe receipt of mRNA vaccines despite PEG-ASNase hypersensitivity

Details

Title: Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity
Authors/Creators: S. Zarnegar‐Lumley (Author/Creator)
C.A. Stone (Author/Creator) - Vanderbilt University Medical Center
C.M. Smith (Author/Creator) - Vanderbilt University Medical Center
L.L. Hall (Author/Creator) - Monroe Carell Jr. Children's Hospital
K.E. Luck (Author/Creator) - Vanderbilt University Medical Center
G. Koo (Author/Creator) - Monroe Carell Jr. Children's Hospital
J.H. Plager (Author/Creator) - Monroe Carell Jr. Children's Hospital
E.J. Phillips (Author/Creator) - Vanderbilt University
D.L. Friedman (Author/Creator) - Vanderbilt University Medical Center
Publication Details: Pediatric Blood & Cancer, Vol.69(7), Art. e29686
Publisher: Wiley
Identifiers: 991005545135207891
Copyright: © 2022 Wiley Periodicals LLC
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

34 Record Views

2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.75 Blood Clotting; 1.75.2119 Heparin-Induced Thrombocytopenia
Web Of Science research areas: Hematology; Oncology; Pediatrics
ESI research areas: Clinical Medicine